Breaking News Instant updates and real-time market news.

KPTI

Karyopharm

$12.57

0.86 (7.34%)

07:14
11/04/19
11/04
07:14
11/04/19
07:14

Karyopharm expects cash, cash equivalents to fund operations into middle of 2021

The company said, "Based on its current operating plans, Karyopharm expects its non-GAAP operating expenses, which excludes stock-based compensation expense, for the full year 2019 to be in the range of $200M to $210M. Karyopharm has not reconciled the full year 2019 outlook for non-GAAP operating expenses to full year 2019 outlook for GAAP operating expenses because Karyopharm cannot reliably predict without unreasonable efforts the timing or amount of the factors that substantially contribute to the projection of stock compensation expense, which is excluded from the full year 2019 outlook for non-GAAP operating expenses. The Company expects that its existing cash, cash equivalents and investments, and the revenue it expects to generate from XPOVIO product sales, will be sufficient to fund its planned operations into the middle of 2021. Additional key activities expected in the remainder of 2019 include supporting the ongoing multiple myeloma regulatory filing for selinexor in Europe, progressing the pivotal Phase 3 BOSTON study in multiple myeloma and submitting an NDA in the U.S. in DLBCL."

  • 04

    Nov

  • 07

    Dec

KPTI Karyopharm
$12.57

0.86 (7.34%)

07/23/19
JPMS
07/23/19
UPGRADE
Target $16
JPMS
Overweight
Karyopharm upgraded to Overweight from Neutral at JPMorgan
JPMorgan analyst Eric Joseph upgraded Karyopharm Therapeutics to Overweight from Neutral and doubled his price target for the shares to $16 from $8. The analyst says his doctor survey supports a "strong" Xpovio launch and long-term outlook.
07/23/19
JPMS
07/23/19
UPGRADE
Target $16
JPMS
Overweight
JPMorgan upgrades Karyopharm after doctor survey, doubles price target
JPMorgan analyst Eric Joseph upgraded Karyopharm Therapeutics to Overweight from Neutral and doubled his price target for the shares to $16 from $8. The analyst conducted a U.S. physician survey assessing Xpovio anticipated use in the approved indication of penta-refractory myeloma, as well as expectations around use in earlier-line settings. The survey of 15 doctors data show favorable reception to Xpovio's clinical profile, with 75% respondents intending to write Xpovio for PR-MM within the next 12 months, Joseph tells investors in a research note. Importantly, nearly all respondents described the side-effect profile as manageable, which is "very encouraging," adds the analyst. He sees a favorable reward/risk profile for Karyopharm shares at current levels.
07/23/19
07/23/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Snap (SNAP) upgraded to Buy from Hold at Stifel with analyst John Egbert saying the company's sales reorganization efforts were already reflected in its prior guidance and the daily active user checks for the quarter appear to be positive. 2. Murphy Oil (MUR) upgraded to Buy from Neutral at Goldman Sachs with analyst Brian Singer saying he believes the company's free cash flow generation is being underappreciated by the market. 3. Karyopharm (KPTI) upgraded to Overweight from Neutral at JPMorgan with analyst Eric Joseph saying he conducted a U.S. physician survey assessing Xpovio anticipated use in the approved indication of penta-refractory myeloma, as well as expectations around use in earlier-line settings. The survey of 15 doctors data show favorable reception to Xpovio's clinical profile, with 75% respondents intending to write Xpovio for PR-MM within the next 12 months. 4. Smith & Nephew (SNN) upgraded to Buy from Hold at Berenberg with analyst Tom Jones saying he believes management and process changes have addressed the company's execution issues. He views Smith & Nephew's portfolio as "highly competitive." 5. Columbia Sportswear (COLM) upgraded to Buy from Neutral at BofA/Merrill with analyst Alexander Perry citing his outlook for the company to generate "significant near-term revenue and EPS upside" amid a strong wholesale environment for Columbia's apparel as well as its "significant" under-penetration in footwear. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
09/24/19
BARD
09/24/19
NO CHANGE
Target $25
BARD
Outperform
Karyopharm Xpovio launch appears strong, says Baird
Baird analyst Michael Ulz said his physician survey regarding the Karyopharm launch of Xpovio is indicating strong early trends. The analyst said there appears to be an early robust, broad adoption with meaningful share gains ahead, and the safety profile is manageable. Ulz said he sees upside to estimates and he reiterated his Outperform rating and $25 price target on Karyopharm shares.

TODAY'S FREE FLY STORIES

IWM

iShares Trust Russell 2000 Index Fund

$163.03

-0.92 (-0.56%)

, RUT

Russell 2000 Index

$0.00

(0.00%)

15:19
12/13/19
12/13
15:19
12/13/19
15:19
Technical Analysis
On The Fly: Weekly technical notes for Russell 2000 »

For the week, the Russell…

IWM

iShares Trust Russell 2000 Index Fund

$163.03

-0.92 (-0.56%)

RUT

Russell 2000 Index

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XLE

Energy Select Sector SPDR

$60.31

-0.55 (-0.90%)

, XLB

S&P Select Materials SPDR

$60.50

-0.42 (-0.69%)

15:18
12/13/19
12/13
15:18
12/13/19
15:18
Technical Analysis
On The Fly: Weekly technical notes for S&P 500 »

The S&P 500 (SPX)…

XLE

Energy Select Sector SPDR

$60.31

-0.55 (-0.90%)

XLB

S&P Select Materials SPDR

$60.50

-0.42 (-0.69%)

XLK

Technology Select Sector SPDR

$89.50

0.61 (0.69%)

XLI

Industrial Select Sector SPDR

$81.67

-0.25 (-0.31%)

XLF

Financial Select Sector

$30.71

-0.11 (-0.36%)

XLU

Utilities SPDR

$63.39

0.53 (0.84%)

SPY

SPDR S&P 500 ETF Trust

$317.32

0.18 (0.06%)

SPX

S&P 500

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

15:17
12/13/19
12/13
15:17
12/13/19
15:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

15:16
12/13/19
12/13
15:16
12/13/19
15:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DELL

Dell Technologies

$49.35

-0.15 (-0.30%)

, NTNX

Nutanix

$32.95

0.34 (1.04%)

15:15
12/13/19
12/13
15:15
12/13/19
15:15
Periodicals
Dell looking to broaden infrastructure lead on Nutanix, CRN says »

Dell Technologies (DELL)…

DELL

Dell Technologies

$49.35

-0.15 (-0.30%)

NTNX

Nutanix

$32.95

0.34 (1.04%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

  • 16

    Dec

  • 09

    Jan

  • 27

    Feb

GOOS

Canada Goose

$40.14

-0.005 (-0.01%)

15:14
12/13/19
12/13
15:14
12/13/19
15:14
Periodicals
DA Davidson analyst sees Canada Goose prices falling, NY Post says »

DA Davidson analyst John…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TSLA

Tesla

$357.87

-1.83 (-0.51%)

15:04
12/13/19
12/13
15:04
12/13/19
15:04
Periodicals
NHTSA to probe December 7 crash of Tesla Model 3, Reuters reports »

The agency will…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Jan

  • 23

    Mar

LYV

Live Nation

$70.64

1.2 (1.73%)

15:02
12/13/19
12/13
15:02
12/13/19
15:02
Periodicals
DoJ preparing to take legal action against Live Nation over ticketing, WSJ says »

The Department of Justice…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

15:00
12/13/19
12/13
15:00
12/13/19
15:00
General news
Treasury Market Summary »

Treasury Market Summary:…

LYV

Live Nation

$70.63

1.19 (1.71%)

14:57
12/13/19
12/13
14:57
12/13/19
14:57
Periodicals
DOJ preparing to take legal action against Live Nation over ticketing, WSJ says »

The Department of Justice…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EGRX

Eagle Pharmaceuticals

$59.90

0.73 (1.23%)

, LLY

Eli Lilly

$121.30

-0.39 (-0.32%)

14:55
12/13/19
12/13
14:55
12/13/19
14:55
Hot Stocks
Eagle Pharmaceuticals reports settlement agreement with Eli Lilly on Pemfexy »

Eagle Pharmaceuticals…

EGRX

Eagle Pharmaceuticals

$59.90

0.73 (1.23%)

LLY

Eli Lilly

$121.30

-0.39 (-0.32%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Dec

  • 17

    Dec

  • 30

    Jan

BMY

Bristol-Myers

$64.01

0.05 (0.08%)

, GILD

Gilead

$65.67

-1.97 (-2.91%)

14:52
12/13/19
12/13
14:52
12/13/19
14:52
Periodicals
Bristol-Myers awarded $585M in damages in patent win over Gilead, Bloomberg says »

Bristol-Myers Squibb…

BMY

Bristol-Myers

$64.01

0.05 (0.08%)

GILD

Gilead

$65.67

-1.97 (-2.91%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Dec

BRFRF

Burford Capital

$0.00

(0.00%)

14:46
12/13/19
12/13
14:46
12/13/19
14:46
Hot Stocks
Muddy Waters' Block says still short Burford Capital »

Muddy Waters' Carson…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ANDE

Andersons

$24.03

-0.35 (-1.44%)

14:37
12/13/19
12/13
14:37
12/13/19
14:37
Hot Stocks
Andersons raises dividend to 17.5c from 17c per share »

The Andersons announces a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TNDM

TNDM

, MDT

Medtronic

$113.56

1.17 (1.04%)

14:36
12/13/19
12/13
14:36
12/13/19
14:36
Recommendations
TNDM, Medtronic analyst commentary  »

Craig-Hallum reiterates…

TNDM

TNDM

MDT

Medtronic

$113.56

1.17 (1.04%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Feb

BMY

Bristol-Myers

$64.19

0.23 (0.36%)

, GILD

Gilead

$65.76

-1.88 (-2.78%)

14:30
12/13/19
12/13
14:30
12/13/19
14:30
Periodicals
Bristol-Myers awarded $585M in damages in patent win over Gilead, Bloomberg says »

Bristol-Myers (BMY) was…

BMY

Bristol-Myers

$64.19

0.23 (0.36%)

GILD

Gilead

$65.76

-1.88 (-2.78%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Dec

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

14:17
12/13/19
12/13
14:17
12/13/19
14:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

14:16
12/13/19
12/13
14:16
12/13/19
14:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VOO

Vanguard S&P 500 ETF

$291.59

0.33 (0.11%)

, IVV

iShares Core S&P 500

$319.25

0.36 (0.11%)

14:08
12/13/19
12/13
14:08
12/13/19
14:08
Technical Analysis
On The Fly: ETF fund flow highlights »

For the second week,…

VOO

Vanguard S&P 500 ETF

$291.59

0.33 (0.11%)

IVV

iShares Core S&P 500

$319.25

0.36 (0.11%)

XLE

Energy Select Sector SPDR

$60.65

-0.21 (-0.35%)

XLF

Financial Select Sector

$30.74

-0.08 (-0.26%)

QQQ

Invesco QQQ Trust

$207.32

0.76 (0.37%)

SPY

SPDR S&P 500 ETF Trust

$317.43

0.29 (0.09%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TNDM

TNDM

14:01
12/13/19
12/13
14:01
12/13/19
14:01
Hot Stocks
Tandem Diabetes up 5% upon resumption following FDA approval news »

After resuming trading,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TNDM

TNDM

14:00
12/13/19
12/13
14:00
12/13/19
14:00
Hot Stocks
Breaking Hot Stocks news story on TNDM »

Tandem Diabetes trading…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VRTX

Vertex

$218.24

-2.19 (-0.99%)

13:57
12/13/19
12/13
13:57
12/13/19
13:57
Hot Stocks
Vertex expands long-term CF medicines reimbursement agreement with Ireland »

Vertex Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Mar

13:55
12/13/19
12/13
13:55
12/13/19
13:55
General news
Action Economics Survey results: »

Action Economics Survey…

SNE

Sony

$67.65

0.34 (0.51%)

, T

AT&T

$38.15

-0.2 (-0.52%)

13:52
12/13/19
12/13
13:52
12/13/19
13:52
On The Fly
Box Office Battle: 'Jumanji' sequel expected to dethrone 'Frozen II' »

Welcome to "Box Office…

SNE

Sony

$67.65

0.34 (0.51%)

T

AT&T

$38.15

-0.2 (-0.52%)

CMCSA

Comcast

$43.59

0.57 (1.33%)

CMCSK

Comcast

$0.00

(0.00%)

LGF.A

Lionsgate

$9.81

-0.18 (-1.80%)

LGF.B

Lionsgate

$9.15

-0.2 (-2.14%)

DIS

Disney

$147.58

1.61 (1.10%)

FOX

Fox Corp.

$36.01

0.05 (0.14%)

FOXA

Fox Corp.

$36.90

0.04 (0.11%)

VIAC

ViacomCBS

$38.51

0.72 (1.91%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 29

    Jan

T

AT&T

$38.20

-0.15 (-0.39%)

13:45
12/13/19
12/13
13:45
12/13/19
13:45
Hot Stocks
AT&T 'well ahead' of 2019 deleveraging goals »

AT&T has supported…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Jan

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.